AR110913A1 - Compuesto aminoglucósido y su uso para prevenir o tratar enfermedades infecciosas - Google Patents

Compuesto aminoglucósido y su uso para prevenir o tratar enfermedades infecciosas

Info

Publication number
AR110913A1
AR110913A1 ARP180100195A ARP180100195A AR110913A1 AR 110913 A1 AR110913 A1 AR 110913A1 AR P180100195 A ARP180100195 A AR P180100195A AR P180100195 A ARP180100195 A AR P180100195A AR 110913 A1 AR110913 A1 AR 110913A1
Authority
AR
Argentina
Prior art keywords
infectious diseases
compound
aminoglucoside
prevent
treat infectious
Prior art date
Application number
ARP180100195A
Other languages
English (en)
Inventor
Masayuki Igarashi
Takashi Ida
Yoshiaki Takahashi
Eijiro Umemura
Original Assignee
Microbial Chem Res Found
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microbial Chem Res Found, Meiji Seika Pharma Co Ltd filed Critical Microbial Chem Res Found
Publication of AR110913A1 publication Critical patent/AR110913A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se describe un compuesto representado por la fórmula general (1), o una de sus sales o solvatos farmacéuticamente aceptables, y una composición farmacéutica de esta, y el uso de esta para prevenir o tratar enfermedades infecciosas y un método para prevenir o tratar enfermedades infecciosas usando estos regímenes. El compuesto representado por la fórmula general (1) tiene una actividad antibacteriana contra bacterias grampositivas y gramnegativas, y es útil en la prevención o el tratamiento de enfermedad infecciosas causada por estas bacterias.
ARP180100195A 2017-01-27 2018-01-26 Compuesto aminoglucósido y su uso para prevenir o tratar enfermedades infecciosas AR110913A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017013030A JP2020055749A (ja) 2017-01-27 2017-01-27 多剤耐性菌に有効な新規アミノグリコシド抗生物質

Publications (1)

Publication Number Publication Date
AR110913A1 true AR110913A1 (es) 2019-05-15

Family

ID=62979533

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100195A AR110913A1 (es) 2017-01-27 2018-01-26 Compuesto aminoglucósido y su uso para prevenir o tratar enfermedades infecciosas

Country Status (4)

Country Link
JP (1) JP2020055749A (es)
AR (1) AR110913A1 (es)
TW (1) TW201839005A (es)
WO (1) WO2018139599A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021138615A (ja) * 2018-05-31 2021-09-16 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 多剤耐性菌に有効なアミノグリコシド抗生物質の製造方法
CN116462721B (zh) * 2023-04-18 2024-02-02 江南大学 抗菌性氨基糖苷衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4360665A (en) * 1981-12-24 1982-11-23 Eli Lilly And Company 4"-N-(Substituted)-apramycin antibiotic derivatives and intermediates therefor
EP2616079B1 (en) * 2010-09-13 2015-10-14 University of Zürich Treatment of bacterial infectious diseases
MX2018001022A (es) * 2015-07-30 2018-05-17 Microbial Chem Res Found Antibiotico aminoglucosido novedoso efectivo contra bacterias resistentes a multiples farmacos.

Also Published As

Publication number Publication date
WO2018139599A1 (ja) 2018-08-02
TW201839005A (zh) 2018-11-01
JP2020055749A (ja) 2020-04-09

Similar Documents

Publication Publication Date Title
PH12016501577A1 (en) Monobactam organic compounds for the treatment of bacterial infections
BR112018005318A2 (pt) ?polipeptídeos de lisina ativos contra bactérias gram-negativas?
CL2018002009A1 (es) Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras.
GT201700132A (es) Compuestos de isoxazol de ácido hidroxámico como inhibidores de lpxc
AR101740A1 (es) Terapia de combinación y composiciones
CO2018001237A2 (es) Derivados de apramicina efectivos contra bacterias resistentes a múltiples fármacos y composiciones de los mismos
EA201990551A1 (ru) Антибиотические соединения
CL2020001147A1 (es) Compuestos antibacterianos
CL2017001276A1 (es) Derivados de benzotiazol antibacterianos
BR112018006276A2 (pt) composto, composição farmacêutica, e, inibidor de subunidade gyrb da dna girase e/ou subunidade pare de topoisomerase iv.
BR112019024549A2 (pt) compostos derivados de glicopeptídeo e usos dos mesmos
AR110913A1 (es) Compuesto aminoglucósido y su uso para prevenir o tratar enfermedades infecciosas
BR112017015744A2 (pt) composto apresentando uma estrutura de fórmula (i), um sal farmaceuticamente aceitável do mesmo ou um isômero ótico do mesmo, composição farmacêutica e uso do composto de fórmula (i) para o tratamento e prevenção de mycobacterium tuberculosis ou outras infecções microbianas
CL2019000857A1 (es) Compuestos heterocíclicos y su uso para prevenir o tratar las infecciones bacterianas.
EA201890412A1 (ru) АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ
PE20190459A1 (es) Inhibidores de beta-lactamasa
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
BR112017016278A2 (pt) agente preventivo e/ou terapêutico de doença imune
BR112018002138A2 (pt) composto 2-(5 s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida, uso, composição farmacêutica e método para a profilaxia ou o tratamento de convulsões
BR112017027899A2 (pt) composições e métodos de uso de corpos lamelares para propósitos terapêuticos
BR112023019720A2 (pt) Uso de análogos de rifamicina em combinação com vancomicina, composição farmacêutica compreendendo esses compostos, método in vitro para prevenir ou inibir o crescimento de uma bactéria e kit
BR112019014738A8 (pt) Composto, forma de dosagem sólida, composição farmacêutica, forma cristalina de composto, método para tratar infecção por hepatite c ou uma condição resultante de uma infecção por hepatite c, composto da fórmula, e, uso de um composto da fórmula
PL425328A1 (pl) Zastosowanie α,β-dihydroksantohumolu
JO3477B1 (ar) مركبات أحادي باكتام عضوية لعلاج العدوى البكتيرية
EA201990712A1 (ru) Лечение рассеянного склероза посредством chs-131

Legal Events

Date Code Title Description
FB Suspension of granting procedure